Latest news with #Niagen
Los Angeles Times
2 days ago
- Health
- Los Angeles Times
Unlocking Cellular Health With Science and Trust
In the longevity and wellness space, Niagen Bioscience is charting a course defined by both scientific rigor and an unwavering commitment to responsible innovation Niagen Bioscience (NASDAQ: NAGE, formerly Chromadex) is a Los Angeles-based company dedicated to advancing the supplements industry using science-backed research into their component ingredients. At the helm is CEO Robert Fried, who says the company's mission is to pioneer NAD+ research and develop transformative NAD-boosting healthy-aging solutions with Niagen, their patented form of nicotinamide riboside (NR). Niagen is the cornerstone of the company's clinically proven product portfolio, Tru Niagen and Niagen IV and injections. During this year's Cannes Lions, Fried sat down with LA Times Studios to discuss how the company is pioneering the NAD+ space and the science and quality backed benefits of its Niagen products. 'NAD+, or nicotinamide adenine dinucleotide, is a co-enzyme found in all living cells – plant and animal – and is involved in all important metabolic processes within the cell, but especially energy metabolism and DNA repair, which are key to supporting mitochondrial health and overall optimal health.' explained Fried. Mitochondria, the 'battery pack of the cell,' combines nutrients from the food you eat and oxygen with NAD+ to produce energy. NAD+ also plays a crucial role in DNA recovery and cellular repair. 'All of these processes that exist within the cell where the cell repairs damage are NAD+ dependent,' Fried emphasized, illustrating how higher NAD+ levels facilitate rapid healing, contrasting youthful recovery with a slower healing process that occurs as we age. This is because NAD+ starts to decline naturally in our 30s, with research showing a dramatic drop of up to 65% by the time we reach age 70. Exposure to stressors like sedentary lifestyle, excess sun exposure, poor diet and environmental factors also impact NAD+ levels. Research shows that NAD+ decline is associated with a decline in overall health and vitality, contributing to the development of conditions and disease. Fried is quick to address a significant industry misconception: 'NAD+ itself is not bioavailable. If you consume NAD+ orally or with an IV, it will not elevate NAD+ levels inside your cells.' He clarified that the NAD+ molecule is too large to penetrate cells, causing NAD+ supplements and IV to be ineffective. Intact NAD+ may even have the potential to cause acute immune inflammatory response, which may be responsible for the uncomfortable side effects associated with NAD+ IV and injections. The solution, according to Fried, is 'to consume an NAD+ precursor molecule that easily gets into the cell and then converts into NAD+, and the best molecule for this is called nicotinamide riboside or NR.' Niagen is patented NR and precisely what Tru Niagen and pharmaceutical-grade Niagen IV and injections offer. With a legacy spanning over 25 years, the company's recent rebranding from ChromaDex to Niagen Bioscience reflects its sharpened focus. 'We're no longer only a reference standards company but an NAD+ company dedicated to addressing one of life's most complex challenges - aging,' said Fried. Niagen Bioscience differentiates itself by operating as an 'R&D lab that specializes in NAD+,' not simply a supplement distributor, he said. Its distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and an external research program helping independent investigators and institutions worldwide uncover the potential of NAD+. 'There is no other company in the supplement space that comes close this level of R&D investment and scientific research,' Fried asserted. The company boasts 38 peer-reviewed, published human clinical studies on oral food-grade Niagen, of which about 95% are completely independent, with another 40 studies currently underway. This level of scientific rigor, he contends, is typically found only in biotech or pharmaceutical companies. Products are tested at the manufacturing facility and then retested upon delivery. Fried notes their marketing: 'We are real. We are genuine. We let the science do the talking.' This approach, he believes, is key to building genuine trust. Niagen Bioscience is exploring Niagen's broader therapeutic potential for its patented NR. Fried reveals extensive clinical studies on the benefits of its patented food-grade NR for specific age-related and orphan diseases (rare conditions characterized by rapid aging). Some of these studies have reached Phase II and III clinical trials. A 52 week, 400-participant, Phase III double-blinded, controlled study on Parkinson's disease recently concluded, conducted with a world-renowned independent researcher. 'That is a level of scientific research ... that you don't see from supplement companies,' Fried emphasized. Niagen Bioscience is also innovating beyond oral supplements. They've developed a pharmaceutical-grade version of nicotinamide riboside, now available as Niagen IV. exclusively at clinics across the U.S. Fried highlighted its advantages: 'If you do an injection or an IV, you're getting the benefits of Niagen directly to the bloodstream.' This results in faster absorption and avoids side effects often associated with direct NAD+ infusions. Fried candidly addresses his concern about a lack of public trust in the dietary supplement industry, citing prevalent unsubstantiated claims, low-quality products, and marketing hype. 'It's my belief that if people genuinely trusted the companies that the industry at large would be so significant because we'd actually have preventative health value,' he states. To combat this, Niagen Bioscience has proposed a 'Trust Alliance' – a coalition of industry players, government and non-profits to test products and ensure claims are met. For Fried, the most meaningful aspect of his journey is receiving letters from individuals who experienced health benefits after taking Tru Niagen. Looking ahead, Niagen Bioscience aims to solidify its position as the 'gold standard in the NAD+ space,' continuing its scientific leadership. 'Our mission is to help every living being around the world age better. We think what could happen in the next five years is very exciting and special,' Fried concluded.
Business Wire
04-08-2025
- Business
- Business Wire
Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference Share Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 12, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit Mr. Fried and Mr. Pamir will also hold one-on-one meetings with institutional investors throughout the conference. To arrange a meeting, please visit the conference website here or contact your CG representative. A replay of the fireside chat webcast will be available on the Niagen Bioscience Investor Relations website, following the event. For additional information on Niagen Bioscience, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen ®, the number one NAD+ boosting oral supplement in the United States † (available at and Niagen Plus ™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).
Yahoo
01-08-2025
- Health
- Yahoo
purelyIV Launches Niagen® IV Therapy - A Breakthrough in NAD+ Cellular Wellness
Metro Detroit's leading mobile IV therapy provider introduces pharmaceutical-grade Niagen® infusions, offering a faster, more efficient, and more comfortable way to boost NAD+ levels at home. ROCHESTER HILLS, Mich., Aug. 1, 2025 /PRNewswire/ -- purelyIV, Metro Detroit's leading mobile IV therapy provider, is proud to announce the launch of Niagen® IV Therapy, a groundbreaking new service designed to efficiently boost NAD+ levels. This innovative treatment uses pharmaceutical-grade nicotinamide riboside chloride (NR) to deliver a faster, more comfortable NAD+ replenishment experience compared to traditional NAD+ IV infusions. Niagen® IV Therapy offers clients a cutting-edge approach to cellular health and wellness. Clinical studies show that Niagen® infusions raise whole-blood NAD+ levels 20% higher than standard NAD+ IV treatments and achieve peak levels within just three hours—while requiring 75% less infusion time. Treatments are typically completed in 30–45 minutes, allowing for a more convenient experience with fewer side effects. "Niagen® IV Therapy represents the next evolution of NAD+ boosting wellness," said Erin Boumansour, co-founder and lead practitioner at purelyIV. "We are excited to bring this advanced therapy to Metro Detroit, offering our clients an efficient and scientifically supported option to enhance energy, support cognitive health, and promote healthy aging—all delivered in the comfort of their home or office." purelyIV's licensed nurses administer Niagen® IV infusions in 500mg and 1000mg doses with 500ml of fluids and electrolytes. Clients can also choose add-on options like NiagenH IV Push and Niagen® Shots for a quick, convenient boost during other IV treatments. With its mobile, in-home service model and commitment to clinical excellence, purelyIV continues to lead the way in providing premium IV therapy solutions designed to meet the unique wellness goals of each client. To learn more about Niagen® IV Therapy or to schedule an appointment, visit Contact:Michael Boumansour***@ Photo(s): Press release distributed by PRLog View original content: SOURCE purelyIV Sign in to access your portfolio
Los Angeles Times
17-07-2025
- Health
- Los Angeles Times
Robert Fried Says Niagen Bioscience Has the Key to Better Aging, and He Has the Science to Prove It
In a recent interview, Robert Fried, CEO of Niagen Bioscience, delves into the science of aging and the pivotal role of a molecule known as NAD (nicotinamide adenine dinucleotide). He explains how NAD is crucial for cellular energy and repair, and how its decline with age contributes to a slower recovery from injuries and the progression of age-related conditions. Fried clarifies a common misconception: NAD itself is not bioavailable when taken orally. Instead, he highlights the importance of a precursor molecule, nicotinamide riboside, which is readily absorbed by cells and converted into NAD. Niagen Bioscience's flagship product, Niagen, is a patented and extensively researched form of nicotinamide riboside. A significant concern for Fried is the lack of integrity in the broader dietary supplement market. He cites a study where less than 1% of competing NAD-boosting products met their label claims, with 40% containing none of the active ingredient. He contrasts this with Niagen Bioscience's commitment to rigorous scientific research, evidenced by 38 peer-reviewed human clinical studies and over 100 preclinical studies. Fried emphasizes that Niagen Bioscience is not just another supplement company. They are singularly focused on NAD and its potential therapeutic benefits. A major four-and-a-half-year study on Parkinson's disease, involving 400 participants, is nearing completion and is expected to provide further evidence of Niagen's potential to address serious age-related diseases. The company's mission, according to Fried, is to educate the public about the importance of NAD and to establish Niagen as the 'gold standard' in the NAD space. He stresses that Niagen is the only patented, legal, and trusted form of nicotinamide riboside, backed by unparalleled scientific research.
Business Wire
08-07-2025
- Business
- Business Wire
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen ®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has entered into a worldwide exclusive commercial license agreement with the Haukeland University Hospital, Bergen, Norway. The agreement secures exclusive rights to a body of proprietary intellectual property, know-how, and data. These data are expected to support future regulatory filings for Conditional Marketing Authorization (CMA), Accelerated Approval (AA), and Marketing Authorization (MA) in the EU under European Medicines Agency (EMA) guidelines for the potential treatment of Parkinson`s Disease (PD) using the Company's patented nicotinamide riboside (Niagen ®) molecule. Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway Share With this license, Niagen Bioscience is the only company with the right to seek regulatory approval for a pharmaceutical NR therapy for PD patients. The company retains the right to either commercialize the drug candidate as a potential therapeutic on its own and/or sublicense the program to a strategic pharmaceutical partner to support regulatory advancement and commercialization. 'This milestone underscores our long-term commitment to translating scientific innovation into meaningful therapeutic solutions,' said Rob Fried, CEO of Niagen Bioscience. 'Through our partnership with Haukeland and its world-renowned researchers, we are taking bold steps into bringing NAD+-boosting therapies to address clinical unmet needs.' Central to this agreement is access to a robust body of scientific data, including findings from the NOPARK trial, the largest and most comprehensive clinical investigation of NAD+ augmentation in persons with early PD to date. The study was recently completed in June 2025 and is expected to be published by the end of 2025. NOPARK is a randomized, double-blind, placebo-controlled phase III clinical trial featuring 400 individuals with early-stage PD across 12 sites in Norway. Randomized to receive either 500 mg of nicotinamide riboside (Niagen) twice daily or placebo for 52 weeks, participants had follow-up assessments at five time points in a one-year period. The primary endpoint is the MDS-UPDRS total score, a gold standard measure of PD progression. 'This is an important milestone in our efforts to bring a potentially disease-modifying treatment for PD closer to patients,' says Professor Charalampos Tzoulis, who leads the NOPARK study and the Neuro-SysMed center, a Norwegian Center of Excellence for Clinical Treatment Research in Neurology at Haukeland University Hospital and the University of Bergen, Norway. 'We are fully committed to advancing knowledge and developing treatments that can truly benefit patients with PD and other neurodegenerative disorders. This agreement represents a significant step in that direction, and we are confident that Niagen Bioscience is well positioned to carry this important science forward - ultimately, for the benefit of patients globally.' This agreement builds on a longstanding collaboration between Haukeland University Hospital's Dr. Charalampos Tzoulis and Niagen Bioscience's external research program, CERP. The first of several material transfer agreements (MTAs) dates to March 2018. Since then, independent research supported by CERP has helped catalyze over 300 research collaborations and more than 35 peer-reviewed clinical studies, including four landmark trials assessing the therapeutic potential of Niagen NR for PD: the phase I/IIa NADPARK study, published in Cell Metabolism, the phase I NR-SAFE study published in Nature Communications, the phase IIa N-DOSE (not yet published), and the phase III NOPARK study (not yet published). In connection with this license agreement, the Company also established a wholly owned subsidiary, which represents a pivotal step in Niagen Bioscience's evolution from supplement science to regulated drug development in pursuit of therapeutics for neurodegenerative diseases with high unmet needs. For additional information on Niagen Bioscience visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the development, regulatory pathway, potential approval, and commercialization of nicotinamide riboside as a treatment for Parkinson's disease; the formation and strategic objectives of NAD Pharmaceuticals, Inc.; the scope and exclusivity of licensing agreements; the potential outcomes and implications of the NOPARK clinical trial; and Niagen Bioscience's broader pharmaceutical ambitions. Forward-looking statements reflect current expectations and projections about future events and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to: the outcomes and interpretation of the NOPARK study and other clinical trials; the ability to obtain regulatory approvals; the timing and success of preclinical and clinical development efforts; market acceptance of new therapies; intellectual property protection and defense; dependence on third parties; supply chain risks; the Company's financial condition and need for additional capital; and general market, economic, and geopolitical conditions. In some cases, forward-looking statements can be identified by terms such as 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'intends,' 'may,' 'plans,' 'seeks,' 'should,' 'will,' and similar expressions, as well as the negative of these terms. These statements speak only as of the date made and are based on current beliefs, assumptions, and information available to management. Niagen Bioscience undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this release, except as required by law. Readers are cautioned not to place undue reliance on such forward-looking statements.
